Nurix CFO sells shares to cover RSU taxes
Nurix Therapeutics, Inc. reported that CFO Hans van Houte exercised three tranches of restricted stock units, converting 10,180 RSUs into the same number of common shares at a $0 exercise price.
Rhea-AI Filing Summary
Nurix Therapeutics, Inc. reported that CFO Hans van Houte exercised three tranches of restricted stock units, converting 10,180 RSUs into the same number of common shares at a $0 exercise price. He then sold 2,845 shares at a weighted average price of $23.3828, within a $23.00–$23.90 range, solely to cover RSU-related tax withholding under a mandatory “sell to cover” arrangement, rather than as discretionary trades.
Positive
- None.
Negative
- None.
Insider Trade Summary
Exercise and sale activity reported; no spread calculated
Exercise and Sale
7 txns
Insider
van Houte Hans
Role
Chief Financial Officer
Sold
2,845 shs ($67K)
Approx. gross sale proceeds
$67K
Approx. exercise cost
$0.00
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units F3, F4, F5 | 3,750 | $0.00 | $0.00 |
| Exercise | Restricted Stock Units F3, F6, F5 | 2,858 | $0.00 | $0.00 |
| Exercise | Restricted Stock Units F3, F7, F5 | 3,572 | $0.00 | $0.00 |
| Exercise | Common Stock | 3,750 | $0.00 | $0.00 |
| Exercise | Common Stock | 2,858 | $0.00 | $0.00 |
| Exercise | Common Stock | 3,572 | $0.00 | $0.00 |
| Sale | Common Stock F1, F2 | 2,845 | $23.3828 | $67K |
Holdings After Transaction:
Restricted Stock Units — 70,562 contracts (Direct);
Common Stock — 44,927 shares (Direct)
Footnotes (7)
- F1. The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.
- F2. Represents the weighted average sale price. The lowest price at which shares were sold was $23.00 and the highest price at which shares were sold was $23.90. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
- F3. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.
- F4. The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
- F5. RSUs do not expire; they either vest or are canceled prior to the vest date.
- F6. The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2025, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
- F7. The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2026, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.
Key Figures
RSUs converted: 10,180 units
Shares sold: 2,845 shares
Weighted average sale price: $23.3828 per share
+3 more
6 metrics
RSUs converted
10,180 units
Total restricted stock units exercised and converted into common stock on 2026-07-30
Shares sold
2,845 shares
Common shares sold on 2026-07-30 to cover RSU tax withholding
Weighted average sale price
$23.3828 per share
Weighted average price for 2,845 shares sold; prices ranged from $23.00 to $23.90
Lowest sale price
$23.00 per share
Lowest price at which shares were sold within the reported sale range
Highest sale price
$23.90 per share
Highest price at which shares were sold within the reported sale range
RSU vesting fraction
1/12 of total award
Each RSU grant vests 1/12 quarterly over three years, subject to continued service
Key Terms
sell to cover, restricted stock units ("RSUs"), weighted average sale price, contingent right
4 terms
sell to cover financial
"tax withholding obligations to be funded by a "sell to cover" transaction"
Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.
restricted stock units ("RSUs") financial
"The RSUs will vest as to 1/12 of the total award quarterly over three years"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
weighted average sale price financial
"Represents the weighted average sale price. The lowest price at which shares were sold"
contingent right financial
"Each restricted stock unit ("RSU") represents a contingent right to receive one share"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Nurix Therapeutics (NRIX) disclose?
Nurix Therapeutics disclosed that CFO Hans van Houte exercised 10,180 RSUs into common stock and sold 2,845 shares. The sale was to satisfy tax withholding obligations tied to RSU vesting under a mandatory “sell to cover” arrangement, not a discretionary stock trade.
How many restricted stock units did the Nurix (NRIX) CFO have vest or convert?
Three RSU tranches totaling 10,180 units vested and were converted into the same number of Nurix common shares. Each RSU represents a contingent right to receive one share of common stock upon vesting, as described in the filing.
What is the vesting schedule of the Nurix (NRIX) CFO’s RSUs?
Each RSU grant vests as to 1/12 of the total award quarterly over three years. The first quarterly increment for the three awards vested on July 30, 2024, July 30, 2025, and July 30, 2026, respectively, subject to continued service.
Were the Nurix (NRIX) CFO’s stock sales under a trading plan?
The filing states sales were made to fund tax withholding via a mandatory “sell to cover” election under the company’s equity plans. It also notes these transactions do not represent discretionary trades by the reporting person.
AI-generated analysis. How Rhea-AI works. Not financial advice.
